Article ISI
CANCER RESEARCH  (2018)

Nivolumab (nivo) plus ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227

Ciuleanu, Tudor Eliade; Pluzanski, Adam; Lee, Jong Seok; Otterson, Gregory; Minenza, Elisa; Burgers, Sjaak; Borghaei, Hossein; Ramalingam, Suresh S.; Brahmer, Julie; O'Byrne, Kenneth J.; Green, George; Szustakowski, Joseph D.; Bhagavatheeswaran, Prabhu; Healey, Diane; Fu, Yali; et. al.